直接抗病毒药物治疗尿毒症合并丙型肝炎2例报告

陈其军; 施翎; 修自力

doi:10.3969/j.issn.1001-5256.2019.05.029

直接抗病毒药物治疗尿毒症合并丙型肝炎2例报告

DOI: 10.3969/j.issn.1001-5256.2019.05.029

宁波市泌尿肾病医院血液净化中心

详细信息

中图分类号: R512.63;R692.5
计量
- 文章访问数: 1042
- HTML全文浏览量: 22
- PDF下载量: 233
- 被引次数: 0
出版历程
- 出版日期: 2019-05-20

Direct-acting antiviral agents for treatment of uremia with hepatitis C: A report of 2 cases

Center of Blood Purification, Ningbo Urinary and Renal Disease Hospital

摘要

摘要: <正>全球有超过1. 3亿人感染HCV[1],其中,我国有2500万人,占全人口的1. 8%～3. 7%[2]。HCV感染可促进慢性肾脏病的发生和发展,而在终末期尿毒症患者中,无论接受血液透析还是肾移植,其HCV感染率均高于其他患者,且HCV感染将
- 抗病毒药 /
- 尿毒症 /
- 丙型肝炎 /
- 病例报告
- antiviral agents /
- uremia /
- hepatitis C /
- case reports

HTML全文

参考文献(19)

[1]THOMSON EC, SMITH JA, KLENERMAN P.The natural history of early hepatitis C virus evolution;lessons from a global outbreak in human immunodeficiency virus-1-infected individuals[J].J Gen Virol, 2011, 92 (10) :2227-2236.

[2]DUAN ZP, JIA ID, HOU J, et al.Current challenges and the management of chronic hepattis C in mainland China[J].JClin Gastroenterol, 2014, 48 (8) :679-686.

[3]FABRIZI F, MARTIN P, MESSA P.New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant[J].Kidney Int, 2016, 89 (5) :988-994.

[4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝病杂志, 2015, 31 (12) :1961-1979.

[5]BORATYN'SKA M, WAKULENKO A, KLINGER M, et al.Chronic allograft dysfunction in kidney transplant recipients:Longterm single-center study[J].Transplant Proc, 2014, 46 (8) :2673-2677.

[6]MORALES JM, FABRIZI F.Hepatitis C and its impact on renal transplantation[J].Nat Rev Nephrol, 2015, 11 (3) :172-182.

[7]CHEN GF.Problems and challenges of hepatitis C treatment in the era of direct antiviral drugs[J].J Med Res, 2016, 45 (4) :1-3. (in Chinese) 陈国凤.DAAs时代丙肝治疗的问题与挑战[J].医学研究杂志, 2016, 45 (4) :1-3.

[8]HE YM, HOU B.PEG-IFNα-2a and ribavirin for decompensated cirrhotic patients with hepatitis C after eliminating complications[J].Clin J Med Offic, 2017, 45 (4) :397-400. (in Chinese) 何妍梅, 侯波.聚乙二醇干扰素α-2a联合利巴韦林治疗失代偿期丙肝肝硬化并发症消除后患者临床观察[J].临床军医杂志, 2017, 45 (4) :397-400.

[9]WEI F, LIU J, LIU F, et al.Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation:An updated meta-analysis[J].PLo S One, 2014, 9 (4) :e90611.

[10]GAGLIO PJ, MOSS N, MCGAW C, et al.Direct-acting antiviral therapy for hepatitis C:Attitudes regarding future use[J].Dig Dis Sci, 2011, 56 (5) :1509-1515.

[11]SUDA G, FURUSYO N, TOYODA H, et al.Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection:A nationwide retrospective study in Japan[J].J Gastroenterol, 2018, 53 (1) :119-128.

[12]TOYODA H, KUMADA T, TADA T, et al.Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis[J].J Gastroenterol, 2016, 51 (7) :741-747.

[13]KAWAKAMI Y, IMAMURA M, IKEDA H, et al.Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C:Pilot study[J].J Viral Hepat, 2016, 23 (11) :850-856.

[14]CARPIO R, PAMUGAS GE, DANGUILAN R, et al.Outcomes of renal allograft recipients with hepatitis C[J].Transplant Proc, 2016, 48 (3) :836-839.

[15]PAPAYANNIS I, PATEL P.Successful treatment of a hepatitis C positive patient who received kidney transplant from a hepatitis C-positive donor:A case report[J].Prog Transplant, 2016, 26 (3) :238-240.

[16]SAWINSKI D, KAUR N, AJETI A, et al.Successful treatment of hepatitis C in renal transplant recipients with directacting antiviral agents[J].Am J Transplant, 2016, 16 (5) :1588-1595.

[17]MAO YJ, ZHANG XF, LIU SD, et al.Efficacy and safety of direct-acting antiviral therapy for hepatitis C after renal transplantation[J].J Shandong Univ:Health Sciences, 2019, 57 (1) :1671-7554. (in Chinese) 卯怡杰, 张旭峰, 刘双德, 等.直接抗病毒治疗肾移植术后丙肝患者的疗效和安全性[J].山东大学学报:医学版, 2019, 57 (1) :1671-7554.

[18]DENG GG, SHEN S, WU JQ, et al.One case of hepatitis Cvirus cure after renal transplantation:Application of new antiviral drugs[J].Ogran Transplantation, 2017, 8 (3) :229-231. (in Chinese) 邓庚国, 申升, 吴家清, 等.肾移植术后丙型病毒性肝炎治愈1例:新型抗病毒药物的应用[J].器官移植, 2017, 8 (3) :229-231.

[19]KOSHINO K, USHIGOME H, MASUDA K, et al.Effective treatment with daclatasvir and asunaprevir in kidney transplant patients infected with hepatitis C virus:A report of two cases[J].Transplant Proc, 2017, 49 (5) :1053-1055.

施引文献

资源附件(0)

访问统计